Furodrag®

Solution for injection.

Diuretic.

Each mL of solution for injection contains:
Furosemide………………… 50 mg
Excipients c.s.p…………….1 mL

Diuretic indicated in the treatment of acute pulmonary, mammary, gestational edema, congestive heart failure and ascites; It is also used as a support therapy in forced diuresis in cases of intoxication of various origins. Indicated in cases of renal failure with oliguria and in diagnostic procedures. In bleeding horses (epistaxis).

Horses and cattle.

Intravenous or intramuscular.

• Dosage of the active ingredient:
  Cattle and horses: 250-500 mg/animal, once or twice daily.
• Product Dosage:
  Cattle and horses: 5 -10 mL/animal, once or twice a day.
  The duration of treatment varies on a case-by-case basis, and depends on the assessment of the treating veterinarian.

• Do not use in patients with anuria; acute glomerular nephritis and severe hepatic failure.
• Do not use in patients who are hypersensitive to furosemide.
• In patients with progressive renal disease whose azotemia and oliguria are increased during furosemide therapy, its administration should be discontinued.
• Do not administer to pregnant or lactating females.

• Furosemide may cause disturbances in fluid and electrolyte balance.
• Metabolic alkalosis can occur due to contraction of extracellular volume. In prolonged treatment it can cause hypokalemia or hyponatremia. Extracellular volume depletion and hyponatremia can lead to decreased blood pressure and tissue perfusion.
• Patients with kidney, heart or liver disease are at increased risk of developing adverse effects.

Furosemide may interact with: Theophylline (potentiates the effect), aminoglycosides or Cisplatin (potentiates ototoxicity and if the volume is high, nephrotoxicity), digitalis glycosides (the diuretic induces hypokalemia which may increase the risk of arrhythmias), Acetylsalicylic acid or other anticoagulants (increases the activity of the anticoagulant), neuromuscular blockers (alteration in the extent of muscle relaxation), corticosteroids (potentiates potassium loss), Insulin (alteration of insulin requirements associated with hyperglycemic effects), Lithium and Propanolol (increase in plasma levels), Probenecid (competition for diuretic secretion in the tubular lumen leading to decreased diuretic effect), non-steroidal anti-inflammatory drugs (decreased diuretic effect), and Thiazide (synergistic diuretic activity).

• Keep out of reach of children and pets.
• In the case of mammary gland oedema related to childbirth, treatment should not exceed 48 hours after childbirth. However, in each case, the doses may be adjusted according to the Veterinary Medical indication.
• Long-term treatment with Furodrag® may cause a decrease in plasma potassium levels, which may require potassium supplementation.
• Use with caution in patients with pre-existing electrolyte or fluid balance abnormalities, impaired liver function (may trigger a hepatic coma), and diabetes mellitus. Patients with conditions that can lead to imbalance

• Wash your hands after administering the product.
• Do not handle people who are hypersensitive to furosemide.
• In case of contact with skin, eyes or mucous membranes, wash immediately with plenty of water.
• Do not handle by pregnant women
• In case of accidental injection, go immediately to a medical center and show the product label.

• Cattle: Meat and milk: 48 hours.
• Do not administer to horses whose meat is intended for human consumption.

Store at a temperature between 15 and 30°C, away from light.
Once opened, use the product within 12 weeks. Discard the unused product after that period of time.

Empty containers can be discarded as household waste, without any special precautions. Do not dispose of containers with product residues on the ground or in waterways. For expired or unused products, contact the manufacturing laboratory.

Sale by prescription to the Veterinary Doctor.

VETERINARY USE

Chile: Reg. SAG No. 1500
Rep. Dominican: Reg. No. 5598
Peru: Reg. SENASA F.14.01.I.0027

Ampoule bottle with 50 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.